Myomo stock analysis
Want to see MYO full AI Analyst Report?
Myomo (MYO) Stock Price & Analysis
MYO Stock Chart & Stats
- Day’s Range
- $1.20 - $1.26
- 52-Week Range
- $0.61 - $1.89
- Previous Close
- $1.25
- Volume
- N/A
- Average Volume (3M)
- 243.68K
- Market Cap
- $50.93M
- Enterprise Value
- $77.43M
- Total Cash (Recent Filing)
- $11.95M
- Total Debt (Recent Filing)
- $21.41M
- Price to Earnings (P/E)
- ―
- Beta
- 1.55
- Next Earnings
- Mar 10, 2027 (Est.)
- EPS Estimate
- -0.06
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue And Order Growth
Record revenue, higher orders, and increased MyoPro unit volume indicate expanding commercial adoption. Sustained growth can improve operating leverage, strengthen referral relationships, and build a larger installed base that supports future recurring demand.
Gross Margin And Operating Leverage
Strong gross margins and slower expense growth demonstrate improving business efficiency as volume scales. If maintained, this operating leverage can reduce losses, support reinvestment in commercial expansion, and bring the company closer to sustainable profitability.
Expanded Payer Access And Referral Channels
Broader payer access and a growing share of recurring referral sources can improve authorization rates and make demand less dependent on individual direct-to-patient leads. These developments strengthen the commercial infrastructure supporting multi-quarter growth.
Bears Say
Weak Balance Sheet And Rising Leverage
The sharply reduced equity cushion and higher leverage leave Myomo more exposed to operating setbacks and financing requirements. A pressured capital structure can constrain investment flexibility and make it harder to absorb continued losses before profitability improves.
Negative Cash Generation And Ongoing Losses
The business is not yet self-funding because operating and free cash flow remain materially negative, while losses continue. Even with improved burn, ongoing cash consumption can require external capital and limit the resources available for growth initiatives.
Uneven Patient-pipeline Efficiency
Lower pipeline additions and weaker advertising conversion could slow future device deliveries if referral growth does not offset the shortfall. This makes revenue expansion more dependent on improving lead quality, sales execution, and recurring referral productivity.
MYO FAQ
What was Myomo’s price range in the past 12 months?
What is Myomo’s market cap?
When is Myomo’s upcoming earnings report date?
How were Myomo’s earnings last quarter?
Is Myomo overvalued?
Does Myomo pay dividends?
What is Myomo’s EPS estimate?
How many shares outstanding does Myomo have?
What happened to Myomo’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Myomo?
What is the TipRanks Smart Score and how is it calculated?
Myomo Stock Smart Score
Company Description
Myomo
Myomo, Inc. is a medical technology company specializing in wearable robotics. The company engineers and manufactures advanced myoelectric orthoses, primarily for individuals in the United States who experience neuromuscular impairments. Its flagship product, MyoPro, is an upper-limb brace that utilizes muscle signals to assist patients with weak or paralyzed arms, thereby enhancing their ability to perform daily activities. These devices aim to restore function for both adult and adolescent patients suffering from various neurological conditions, including stroke, spinal cord injury, traumatic brain injury, and brachial plexus injuries. Myomo distributes its innovative solutions through a network that includes orthotics and prosthetics providers, rehabilitation hospitals, the Veterans Health Administration, and additional distributors. Established in 2004, Myomo, Inc. maintains its corporate headquarters in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Paul R. Gudonis
- Employees
- 195
- Website
- www.myomo.com
- Address
- 45 Blue Sky Dr., Burlington, MA, 01803, US
Myomo (MYO) Earnings & Revenues
MYO Earnings Call
Earnings Call SentimentPositive
The call was predominantly positive, with record revenue and orders, substantial gross-margin expansion, improved operating loss and cash usage, expanded payer access, and continued progress in recurring referral sources. The main negatives were lower pipeline additions, direct-to-patient lead-generation inefficiency, a net loss that included a noncash derivative charge, continued cash use, and expected fourth-quarter operating expense increases.
View all MYO earnings summariesMYO Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 7 | 5 | 10 |
| Technical Analysis | 4 | 5 | 1 |
| Moving Averages | 3 | 0 | 9 |










